Preliminary analysis of immune activation in early onset type 2 diabetes

International Journal of Circumpolar Health

Volumn 72, Issue SUPPL.1, 2013, Pages

  Rempel, Julia D ^a,b   Packiasamy, Juliet ^a   Dean, Heather J ^b   McGavock, Jonathon ^b   Janke, Alyssa ^a   Collister, Mark ^a,b   Wicklow, Brandy ^b   Sellers, Elizabeth A C ^b  

^a Manitoba Institute of Child Health   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Early onset type 2 diabetes; Interleukin 1beta; TLR4

Indexed keywords

ADIPONECTIN; INTERLEUKIN 1BETA; LEPTIN; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; AGE; AMERICAN INDIAN; ARTICLE; BLOOD; BODY MASS; CASE CONTROL STUDY; CELLULAR IMMUNITY; EARLY ONSET TYPE 2 DIABETES; FEMALE; HUMAN; IMMUNOLOGY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; STATISTICS;

EARLY ONSET TYPE 2 DIABETES; INTERLEUKIN 1BETA; TLR4;

ADIPONECTIN; ADOLESCENT; AGE FACTORS; BODY MASS INDEX; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; IMMUNITY, CELLULAR; INDIANS, NORTH AMERICAN; INTERLEUKIN-1BETA; LEPTIN; MALE; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84881290776     PISSN: 12399736     EISSN: 22423982     Source Type: Journal    
DOI: 10.3402/ijch.v72i0.21190     Document Type: Article

References (47)

1. Ley SH, Harris SB, Mamakeesick M, Noon T, Fiddler E, Gittelsohn J, et al. Metabolic syndrome and its components as predictors of incident type 2 diabetes mellitus in an Aboriginal community. CMAJ. 2009;180:617-24.
2. Vanderloo SE, Johnson JA, Reimer K, McCrea P, Nuernberger K, Krueger H, et al. Validation of classification algorithms for childhood diabetes identified from administrative data. Pediatr Diabetes. 2012;13:229-34.
3. Amed S, Dean HJ, Panagiotopoulos C, Sellers EA, Hadjiyannakis S, Laubscher TA, et al. Type 2 diabetes, medication-induced diabetes, and monogenic diabetes in Canadian children: a prospective national surveillance study. Diabetes Care. 2010;33:786-91.
4. Sellers E, Dean H. Clinical and demographic characteristics of type 2 diabetes in youth at diagnosis in Manitoba and Northwestern Ontario (2006-2011). Can J Diab. 2012;36: 114-8.
5. Aborsangaya KB, Dembinski I, Khatkar S, Alphonse MP, Nickerson P, Rempel JD. Impact of aboriginal ethnicity on HCV core-induced IL-10 synthesis: interaction with IL-10 gene polymorphisms. Hepatology. 2007;45:623-30.
6. Rempel JD, Hawkins K, Lande E, Nickerson P. The potential influence of KIR cluster profiles on disease patterns of Canadian Aboriginals and other indigenous peoples of the Americas. Eur J Hum Genet. 2011;19:1276-80.
7. Shields M. Measured obesity: overweight Canadian children and adolescents. Statistics Canada. Cat. No. 82-6620-MWE2005001. Anal Stud Rep. 2005;1:1-34.
8. Willows ND, Marshall D, Raine K, Ridley DC. Diabetes awareness and body size perceptions of Cree schoolchildren. Health Educ Res. 2009;24:1051-8.
9. Wahi G, Zorzi A, Macnab A, Panagiotopoulos C. Prevalence of type 2 diabetes, obesity and the metabolic syndrome among Canadian First Nations children in a remote Pacific coast community. Paediatr Child Health. 2009;14:79-83.
10. Dean HJ, Young TK, Flett B, Wood-Steiman P. Screening for type-2 diabetes in aboriginal children in northern Canada. Lancet. 1998;352:1523-4.
11. Young TK, Dean HJ, Flett B, Wood-Steiman P. Childhood obesity in a population at high risk for type 2 diabetes. J Pediatr. 2000;136:365-9.
12. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med. 2008;14:741-51.
13. Mangge H, Schauenstein K, Stroedter L, Griesl A, Maerz W, Borkenstein M. Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis. Exp Clin Endocrinol Diabetes. 2004;112:378-82.
14. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112: 1796-808.
15. Bertola A, Bonnafous S, Anty R, Patouraux S, Saint-Paul MC, Iannelli A, et al. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One. 2010;5:e13577.
16. Dasu MR, Jialal I. Free fatty acids in the presence of high glucose amplify monocyte inflammation via toll-like receptors. Am J Physiol Endocrinol Metab. 2011;300:E145-54.
17. Nieto-Vazquez I, Fernandez-Veledo S, Kramer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M. Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiol Biochem. 2008;114:183-94.
18. Vanderford NL. Defining the regulation of IL-1beta-and CHOP-mediated beta-cell apoptosis. Islets. 2010;2:334-6.
19. Eder K, Baffy N, Falus A, Fulop AK. The major inflammatory mediator interleukin-6 and obesity. Inflamm Res. 2009;58: 727-36.
20. Dasu MR, Devaraj S, Park S, Jialal I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care. 2010;33: 861-8.
21. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116:3015-25.
22. Wong FS, Wen L. Toll-like receptors and diabetes. Ann NY Acad Sci. 2008;1150:123-32.
23. Stringer DM, Sellers EA, Burr LL, Taylor CG. Altered plasma adipokines and markers of oxidative stress suggest increased risk of cardiovascular disease in First Nation youth with obesity or type 2 diabetes mellitus. Pediatr Diabetes. 2009;10: 269-77.
24. Larcombe L, Rempel JD, Dembinski I, Tinckam K, Rigatto C, Nickerson P. Differential cytokine genotype frequencies among Canadian Aboriginal and Caucasian populations. Genes Immun. 2005;6:140-4.
25. Dean HJ, Sellers EA. Comorbidities and microvascular complications of type 2 diabetes in children and adolescents. Pediatr Diabetes. 2007;8(Suppl 9):35-41.
26. Chuback J, Embil JM, Sellers E, Trepman E, Cheang M, Dean H. Foot abnormalities in Canadian Aboriginal adolescents with type 2 diabetes. Diabet Med. 2007;24:747-52.
27. Dart A, Sellers E, Brownell M, Rigatto C, Dean H, Martens P. High burden of renal complications in youth onset type 2 diabetes. Diabetes Care. 2012;35:1265-71.
28. Hegele RA, Cao H, Harris SB, Hanley AJ, Zinman B, Connelly PW. The private hepatocyte nuclear factor-1alpha G319S variant is associated with plasma lipoprotein variation in Canadian Oji-Cree. Arterioscler Thromb Vasc Biol. 2000; 20:217-22.
29. Sellers EA, Triggs-Raine B, Rockman-Greenberg C, Dean HJ. The prevalence of the HNF-1alpha G319S mutation in Canadian aboriginal youth with type 2 diabetes. Diabetes Care. 2002;25:2202-6.
30. Troiano RP, Flegal KM. Overweight children and adolescents: description, epidemiology, and demographics. Pediatrics. 1998;101:497-504.
31. Krueger C, Collister M, Minuk G, Janke A, Lerner J, Wong S, Rempel J. The interaction of obesity and HCV protein induced TNF-a in treatment outcomes for hepatitis C virus infection. Submitted.
32. Pyrzak B, Ruminska M, Popko K, Demkow U. Adiponectin as a biomarker of the metabolic syndrome in children and adolescents. Eur J Med Res. 2010;15(Suppl 2):147-51.
33. Giordano P, Del Vecchio GC, Cecinati V, Delvecchio M, Altomare M, De Palma F, et al. Metabolic, inflammatory, endothelial and haemostatic markers in a group of Italian obese children and adolescents. Eur J Pediatr. 2011;170: 845-50.
34. Kopp HP, Krzyzanowska K, Mohlig M, Spranger J, Pfeiffer AF, Schernthaner G. Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes (Lond). 2005;29:766-71.
35. Moran O, Phillip M. Leptin: obesity, diabetes and other peripheral effects-a review. Pediatr Diabetes. 2003;4:101-9.
36. Ley SH, Harris SB, Connelly PW, Mamakeesick M, Gittelsohn J, Hegele RA, et al. Adipokines and incident type 2 diabetes in an Aboriginal Canadian [corrected] population: the Sandy Lake Health and Diabetes Project. Diabetes Care. 2008;31: 1410-5.
37. Popko K, Gorska E, Stelmaszczyk-Emmel A, Plywaczewski R, Stoklosa A, Gorecka D, et al. Proinflammatory cytokines Il-6 and TNF-alpha and the development of inflammation in obese subjects. Eur J Med Res. 2012;15(Suppl 2):120-2.
38. Gonzalez M, Del Mar Bibiloni M, Pons A, Llompart I, Tur JA. Inflammatory markers and metabolic syndrome among adolescents. Eur J Clin Nutr. 2012;66:1141-5.
39. Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Gyori G, et al. Human adipose tissue macrophages are of an antiinflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (Lond). 2007;31: 1420-8.
40. Fogeda M, Gallart L, Gutierrez C, Vendrell J, Simon I, Garcia-Espana A, et al. High expression of tumor necrosis factor alpha receptors in peripheral blood mononuclear cells of obese type 2 diabetic women. Eur Cytokine Netw. 2004;15:60-6.
41. Taube A, Schlich R, Sell H, Eckardt K, Eckel J. Inflammation and metabolic dysfunction: links to cardiovascular diseases. Am J Physiol Heart Circ Physiol. 2012;302:H2148-65.
42. Koleva-Georgieva DN, Sivkova NP, Terzieva D. Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy. Folia Med (Plovdiv). 2011;53:44-50.
43. Dinarello CA. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol. 2011;41:1203-17.
44. De Nardo D, Latz E. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol. 2011;32:373-9.
45. Stienstra R, Tack CJ, Kanneganti TD, Joosten LA, Netea MG. The inflammasome puts obesity in the danger zone. Cell Metab. 2012;15:10-8.
46. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517-26.
47. Ehses JA, Lacraz G, Giroix MH, Schmidlin F, Coulaud J, Kassis N, et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci USA. 2009;106:13998-4003.